ArticleAdvances in therapy2026
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionNo head-to-head clinical trials have compared CD19-directed chimeric antigen receptor (CAR) T cell therapies for treatment of follicular lymphoma (FL). We conducted matching-adjusted indirect comparisons (MAICs) between lisocabtagene maraleucel (liso-cel), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel), to establish their relative efficacy and safety in patients with third-line or later (3L+) relapsed or refractory (R/R) FL.
methodsSources included individual patient data from TRANSCEND FL (NCT04245839) for liso-cel, summary-level data from ZUMA-5 (NCT03105336) for axi-cel, and summary-level data from ELARA (NCT03568461) for tisa-cel. For each MAIC, TRANSCEND FL patients who met inclusion/exclusion criteria for the comparator study were included. MAICs adjusted for clinically relevant prognostic factors identified a priori to minimize population differences between studies.
resultsAfter adjustment, liso-cel had a higher complete response (CR) rate than axi-cel (response ratio [RR] 1.24, 95% confidence interval [CI] 1.07‒1.43) and tisa-cel (RR 1.36, 95% CI 1.11‒1.68) and a higher overall response rate (ORR) than tisa-cel (RR 1.12, 95% CI 1.01‒1.24). Estimates numerically favored liso-cel for progression-free survival, duration of response, overall survival, and time to next treatment, though were not statistically significant. Liso-cel demonstrated better safety than axi-cel, with significantly reduced odds ratios (ORs) of grade ≥ 3 cytokine release syndrome (CRS; OR 0.07, 95% CI 0.01‒0.58), tocilizumab use for CRS (OR 0.20, 95% CI 0.09‒0.44), any-grade neurological events (NEs; OR 0.14, 95% CI 0.05‒0.38), and infections (OR 0.42, 95% CI 0.19‒0.93). Liso-cel and tisa-cel had similar safety profiles overall, excluding any-grade NEs, which was significantly lower for liso-cel (OR 0.19, 95% CI 0.08‒0.45).
conclusionAfter adjustment for population differences, liso-cel demonstrated a higher CR rate and numerically favorable trends of survival compared to axi-cel and tisa-cel with improved safety compared to axi-cel, and similar safety compared to tisa-cel. These findings underscore liso-cel as a potentially preferred CAR T cell therapy for 3L+ R/R FL. Graphical Abstract available for this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.